Hori­zon hits the gas ped­al on re­newed ear­ly-stage R&D, en­list­ing a Mitch Gold biotech in a $1.5B+ deal

Hori­zon Ther­a­peu­tics is no stranger to swing­ing deals, and on Thurs­day the Irish biotech grabbed it­self a new part­ner to help build out its ear­ly-stage pipeline.

In a col­lab­o­ra­tion ex­pect­ed to bring up to four new pro­grams in­to the fold, Hori­zon is team­ing up with Alpine Im­mune Sci­ences in a deal worth po­ten­tial­ly more than $1.5 bil­lion, the com­pa­nies an­nounced Thurs­day morn­ing. Hori­zon will pay $25 mil­lion up­front in cash and make a $15 mil­lion eq­ui­ty in­vest­ment, with promis­es of up to $381 mil­lion mile­stones for each can­di­date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER